Friday, July 10, 2026

Drug profile · INN

autologous

autologous is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 8
Pipeline programs 70
News articles 0
Drug details — autologous
Class
Route
Patents
8
Programs
70
Data quality
0.70

Quick answer

autologous is an FDA-listed pharmaceutical active ingredient.

Key facts

INN autologous

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) Phase 3 · Lisata Therapeutics · Stage IV Melanoma
  2. Autologous Peripheral Blood Stem Cell injection Phase 3 · Hospital Authority · Acute Myocardial Infarction
  3. Expanded autologous adipose-derived adult stem cells (eASCs) Phase 3 · Takeda · Complex Perianal Fistula
  4. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT) Phase 3 · Disc Medicine · Symptomatic articular cartilage lesion of the knee (femoral
  5. Suspension of autologous mononuclear cells separated from bone marrow aspirate Phase 3 · George Institute for · diabetic foot syndrome, lower limb ischemia
  6. eythrocytapheresis Phase 3 · Atrium Therapeutics · Pre Operative Autologous Donation
  7. Autologous (self) mononuclear cells derived from umbilical cord blood Phase 2 · Regeneron Ireland Designated · Hypoplastic Left Heart Syndrome
  8. Autologous BCMA-targeting CAR T cells Phase 2 · Chinese Academy of · Multiple Myeloma in Relapse

Related patents

  1. US 12385010

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12186342

    Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12173314

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12110504

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 8852936

    Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8541185

    Method of predicting responsiveness to autologous adoptive cell transfer therapy

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 7264820

    Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline

    Expires Mon Aug 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 6277368

    Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

    Expires Mon Aug 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is autologous?

autologous is an FDA-listed pharmaceutical active ingredient.